AnneFreyLuetkemeyerMD

Infectious Disease • San Francisco, CA

Assistant Professor, Medicine, UCSF School of Medicine

Join to view full profile

Dr. Luetkemeyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Luetkemeyer's full profile

Already have an account?

Office
995 Potrero Ave
Box 0874
San Francisco, CA 94110
Phone+1 415-476-4082

Fax+1 415-476-6953

Education & Training

University of California (San Francisco)Fellowship, Infectious Disease, 2003 - 2006
University of California (San Francisco)Residency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

Certifications & Licensure

CA State Medical License 2001 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection Start of enrollment: 2008 Apr 01
Completed
Phase 4
A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C Start of enrollment: 2014 Aug 01
Withdrawn
Phase 4
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Start of enrollment: 2019 Nov 26
COMPLETED
PHASE4

Publications & Presentations

PubMed

Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and op...
Anne F Luetkemeyer, Deborah Donnell, Stephanie E Cohen, Julia C Dombrowski, Cole Grabow
The Lancet. Infectious Diseases. 2025-03-24
2 citations
In Vitro Exposure of Treponema pallidum to Subbactericidal Doxycycline Did Not Induce Resistance: Implications for Doxycycline Postexposure Prophylaxis.
Lauren C Tantalo, Anne F Luetkemeyer, Nicole A P Lieberman, B Ethan Nunley, Carlos Avendaño
The Journal of Infectious Diseases. 2025-03-17
Another Tool for the Sexual Health Toolkit: US Health Care Provider Knowledge and Attitudes About Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Tr...
Rodney Perkins, Kristin Beima-Sofie, Katerina Christopoulos, Stephanie E Cohen, Aurnell Dright
Sexually Transmitted Diseases. 2025-03-01

Press Mentions

Antibiotic Cuts Risk of HIV, STDs After Exposure, Study SaysMay 8th, 2023
Doxy-PEP for STIs and More: Dr. Dieffenbach’s Highlights from Day 1 of CROI 2023February 21st, 2023
Meta-Analysis Supports COVID-19 Mortality Benefit with IL-6 InhibitorsJuly 15th, 2021
Join now to see all

Grant Support

The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratiosUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with menUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2019–2025